| 1 |
NCT03240549 |
Not yet recruiting |
Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease |
- Non-small Cell Lung Cancer Metastatic
|
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate
- Duration of Response Duration of Response
- Progression Free Survival.
- (and 2 more...)
|
159 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03240549 |
121-2016007 |
|
August 2017 |
August 31, 2018 |
September 30, 2019 |
August 7, 2017 |
August 7, 2017 |
|
|
| 2 |
NCT00021060 |
Completed |
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer |
- Adenocarcinoma of the Lung
- Bronchoalveolar Cell Lung Cancer
- Large Cell Lung Cancer
- (and 3 more...)
|
- Drug: paclitaxel
- Drug: carboplatin
- Biological: bevacizumab
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival
- Grade 4 or 5 toxicities assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
|
842 |
All |
18 Years and older (Adult, Senior) |
NCT00021060 |
NCI-2012-02947
E4599
U10CA021115
CDR0000068744 |
|
August 2002 |
September 2006 |
|
January 27, 2003 |
February 27, 2013 |
|
- Eastern Cooperative Oncology Group
Boston, Massachusetts, United States
|
| 3 |
NCT00424840 |
Completed |
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy |
|
|
Interventional |
Phase 1
Phase 2 |
- University of Massachusetts, Worcester
- Millennium Pharmaceuticals, Inc.
- Genentech, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective is to estimate the efficacy and safety of combination therapy with Carboplatin, bortezomib and Bevacizumab as first line therapy in advanced NSCLC. The primary endpoints are response rate and progression-free survival (PFS).
|
19 |
All |
18 Years and older (Adult, Senior) |
NCT00424840 |
UM200601 |
|
June 2006 |
March 2014 |
March 2014 |
January 22, 2007 |
November 19, 2014 |
|
- University of Massachusetts Medical School
Worcester, Massachusetts, United States
|
| 4 |
NCT02316327 |
Completed |
Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab |
- Non-Small Cell Lung Cancer (NSCLC)
|
- Drug: gemcitabine, cisplatin and bevacizumab
|
Interventional |
Phase 4 |
- Fundacion Clinic per a la Recerca Biomédica
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate blood supply, blood volume, time to peak flow increase and permeability and relation with the objective response to treatment (RC+RP)
- To evaluate the response to treatment in terms of blood supply, blood volume and time to peak flow increase and permeability.
- To evaluate the blood supply, blood volume, time to peak flow increase, permeability related with PFS and OS.
- (and 2 more...)
|
19 |
All |
18 Years and older (Adult, Senior) |
NCT02316327 |
IMPACT
2012-000459-15 |
|
July 2013 |
September 2016 |
October 2016 |
December 12, 2014 |
October 5, 2016 |
|
- Hospital Clinic
Barcelona, Spain
|
| 5 |
NCT00653939 |
Completed
Has Results |
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer |
|
- Drug: Fosbretabulin
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Bevacizumab
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) in the Intent-to-Treat Population
- Best Overall Tumor Response Rate (RR) in the Intent-to-Treat Population
- Overall Survival (OS) Using a Multivariate Cox Regression Model in the Intent-to-Treat Population
- (and 3 more...)
|
63 |
All |
18 Years and older (Adult, Senior) |
NCT00653939 |
OXC401-216 |
FALCON |
March 2008 |
July 2011 |
October 2011 |
April 7, 2008 |
February 9, 2015 |
February 9, 2015 |
- Southbay Oncology Hematology
Campbell, California, United States - Pacific Coast Hematology and Oncology Medical Group
Fountain Valley, California, United States - UCLA Division of Hematology and Oncology
Los Angeles, California, United States - (and 12 more...)
|
| 6 |
NCT02591615 |
Recruiting |
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC |
- Non-Small Cell Lung Cancer
|
- Drug: MK-3475
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: Pemetrexed
|
Interventional |
Phase 2 |
- Alliance Foundation Trials, LLC.
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR) per RECIST 1.1
- Compare Progression-Free Survival (PFS) per RECIST 1.1
- Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT02591615 |
AFT-09 |
|
March 2016 |
April 2019 |
December 2019 |
October 29, 2015 |
April 13, 2018 |
|
- UCSD Moores Cancer Center
La Jolla, California, United States - The University of Chicago Medical Center
Chicago, Illinois, United States - NorthShore University HealthSystem
Evanston, Illinois, United States - (and 16 more...)
|
| 7 |
NCT03447678 |
Not yet recruiting |
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. |
- Non Small Cell Lung Cancer (NSCLC)
|
|
Interventional |
Phase 2 |
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Immune biomarkers
- Immune biomarkers distribution between pre and post Pembrolizumab treatment
- Activity endpoints
- (and 3 more...)
|
65 |
All |
18 Years and older (Adult, Senior) |
NCT03447678 |
INT 178-17 |
PEOPLE |
March 1, 2018 |
March 1, 2021 |
March 1, 2021 |
February 27, 2018 |
February 28, 2018 |
|
- National Cancer Institute
Milan, Italy
|
| 8 |
NCT02577341 |
Recruiting |
Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer |
- Non-small-cell Lung Cancer
|
- Drug: Nimotuzumab
- Drug: docetaxel and cisplatin
- Radiation: daily RT (65Gy in 25 fractions) to the chest
- Drug: placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival
- Objective Response Rate
- progression-free survival
- (and 2 more...)
|
150 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02577341 |
2014-FXY-061 |
|
August 2015 |
July 2020 |
July 2020 |
October 16, 2015 |
April 18, 2017 |
|
- Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China
|
| 9 |
NCT01660399 |
Unknown † |
Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy |
- Squamous Cell Lung Cancer
|
- Drug: Boanmycin
- Drug: Docetaxel
|
Interventional |
Phase 2 |
- Tianjin Medical University Cancer Institute and Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- disease free survival
- overall survival
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT01660399 |
CIH-CHP-201205001 |
|
August 2012 |
November 2016 |
December 2016 |
August 8, 2012 |
December 22, 2015 |
|
- Department of Pulmonary Medical Oncology, Tianjin Medical University Cancer Hospital
Tianjin, Tianjin, China
|
| 10 |
NCT00908219 |
Withdrawn |
A Study of Bevacizumab to Prevent Malignant Ascites |
|
|
Interventional |
Phase 2 |
- Baylor College of Medicine
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- To determine the repeat paracentesis response rate defined as a doubling of the patient's baseline time to repeat paracentesis.
- To assess the time to the need for the first repeat abdominal paracentesis after the start of Bevacizumab therapy as compared with historical control data.
- To analyze the mean number of paracentesis procedures required in each patient over the course of three months.
- To assess the effect of anti-VEGF therapy on quality of life in patients with malignant ascites.
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT00908219 |
H-21728
AVF4534s |
|
July 2009 |
February 2011 |
February 2011 |
May 25, 2009 |
June 3, 2015 |
|
- Baylor College of Medicine
Houston, Texas, United States - Ben Taub General Hospital
Houston, Texas, United States - Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas, United States
|
Create an RSS feed from your search for:
Download the search results for: